VORASIDENIB

Information current as at: 1 April 2026

PBAC meeting date: July 2025
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Voranigo®
Form and strength:
Please search for and view the medicine's Public Summary Document (PSD) for more information
Condition/indication:
(therapeutic use)
  • Astrocytoma or oligodendroglioma
Listing requested:
Please see PSD for more information
Funding program:
Please see PSD for more information
Request authority level:
Please see PSD for more information
PBAC submission type:
New PBS listing (–)
Comment:
--
Submission sponsor:
SERVIER LABORATORIES (AUST.) PTY. LTD.
Other PBAC consideration:
--

Progress Details

Submission received for:
July 2025 PBAC meeting
Opportunity for consumer comment:
Open 02/04/2025 and close 28/05/2025 (see PBS Website)
PBAC meeting:
Held on 09/07/2025
PBAC outcome published:
Not Recommended (see PBAC Outcomes)
Lodgement of required documentation:
Not applicable
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information

Case ID: a1085

Page last updated: 31 March 2026

v.9.19